SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aurora Biosciences (ABSC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (13)9/26/1997 5:09:00 PM
From: Boyce Burge   of 359
 
James... I meant the hype that comes every January when H&Q and others have their biotech conferences. If you bought ARQL then, as many did you paid $22-24 for it -- after Feb it dropped to 13, and has never quite struggled back to its Jan-Feb high.

The point I'm making is not that ARQL or TRPS are bad companies to own, ...but that they are bad companies to buy in January, or to sell in the summer. People who buy biotech on analysts recommendations and then sell when the stock dissapoints can easily lose half their capital each year.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News